Enzymatically activatable diagnostic probes

Current Pharmaceutical Biotechnology

Volumn 13, Issue 4, 2012, Pages 523-536

  Thorek, D L J ^a   Grimm, J ^b  

^a Department of Radiology ^*  (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Molecular specificity; Multimodality; Nanoparticles; Signal to noise

Indexed keywords

CATHEPSIN D; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GADOLINIUM; GADOLINIUM PENTETATE; GELATINASE A; GOLD NANOPARTICLE; GREEN FLUORESCENT PROTEIN; INDOCYANINE GREEN; MATRILYSIN; MATRIX METALLOPROTEINASE; QUANTUM DOT; RADIOISOTOPE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TETRAXETAN;

BIOLUMINESCENCE; CHRONIC MYELOID LEUKEMIA; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME SUBSTRATE; FLUORESCENCE RESONANCE ENERGY TRANSFER; GASTROINTESTINAL STROMAL TUMOR; MAGNETIC FIELD; MOLECULAR IMAGING; MOLECULAR PROBE; NEAR INFRARED SPECTROSCOPY; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMERIZATION; POSITRON EMISSION TOMOGRAPHY; PROTEIN CLEAVAGE; PROTEIN PHOSPHORYLATION; RELAXATION TIME; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; COLORING AGENTS; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMANS; LUMINESCENT PROTEINS; MOLECULAR IMAGING; RADIOISOTOPES;

EID: 84857701418     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112799436339     Document Type: Review

References (170)

1. Herschman, H. R. Molecular imaging: looking at problems, seeing solutions. Science, 2003, 302 (5645), 605-608.
2. Weissleder, R. Molecular imaging in cancer. Science, 2006, 312 (5777), 1168-1171.
3. [Fruton, J. S. Proteins, Enzymes, Genes: The Interplay of Chemistry and Biology. Yale University Press: New Haven, CT, 1999; p xii, 783 p.
4. Chang, A.; Scheer, M.; Grote, A.; Schomburg, I.; Schomburg, D. BRENDA, AMENDA and FRENDA the enzyme information system: new content and tools in 2009. Nucl. Acids Res., 2009, 37 (suppl. 1), D588-592.
5. Barton, N.; Brady, R.; Dambrosia, J.; Di Bisceglie, A.; Doppelt, S.; Hill, S.; Mankin, H.; Murray, G.; Parker, R.; Argoff, C. Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease. N. Engl. J. Med., 1991, 324 (21), 1464-1470.
6. Mohamed, M. M.; Sloane, B. F. Cysteine cathepsins: multifunctional enzymes in cancer. Nat. Rev. Cancer, 2006, 6 (10), 764-775.
7. [Haugland, R. P.; Spence, M. T. Z.; Johnson, I. D.; Basey, A. The handbook: A Guide to Fluorescent Probes and Labeling Technologies. 10th ed.; Molecular Probes: Eugene, OR, 2005; p iv, 1126 p.
8. Van Noorden, C. J. F., Imaging Enzymes at Work: Metabolic Mapping by Enzyme Histochemistry. J. Histochem. Cytochem., 2010, 58 (6), 481-497.
9. Bancroft, J. D.; Stevens, A. Theory and Practice of Histological Techniques. 3rd ed.; Churchill Livingstone: Edinburgh; New York, 1990; p xiv, 726 p.
10. Porstmann, T.; Kiessig, S. T. Enzyme immunoassay techniques an overview. J. Immunol. Methods, 1992, 150 (1-2), 5-21.
11. Hillisch, A.; Lorenz, M.; Diekmann, S. Recent advances in FRET: distance determination in protein-DNA complexes. Curr. Opin. Struct. Biol., 2001, 11 (2), 201-207.
12. Weissleder, R. A clearer vision for in vivo imaging. Nat. Biotech., 2001, 19 (4), 316-317.
13. Mitra, R. D.; Silva, C. M.; Youvan, D. C. Fluorescence resonance energy transfer between blue-emitting and red-shifted excitationderivatives of the green fluorescent protein. Gene, 1996, 173(1), 13-17.
14. Zhang, B., Design of FRET-based GFP probes for detection of protease inhibitors. Biochem. Biophys. Res. Commun., 2004, 323(2), 674-678.
15. Tyagi, S.; Kramer, F. R. Molecular beacons: probes that fluoresce upon hybridization. Nat. Biotech., 1996, 14(3), 303-308.
16. Chen, A. K.; Behlke, M. A.; Tsourkas, A. Efficient cytosolic delivery of molecular beacon conjugates and flow cytometric analysis of target RNA. Nucl. Acids Res., 2008, 36(12), e69
17. Matayoshi, E.; Wang, G.; Krafft, G.; Erickson, J. Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer. Science, 1990, 247(4945), 954-958.
18. Reddy, V. Y.; Zhang, Q. Y.; Weiss, S. J. Pericellular mobilization of the tissue-destructive cysteine proteinases, cathepsins B, L, and S, by human monocyte-derived macrophages. Proc. Natl. Acad. Sci. USA, 1995, 92(9), 3849-3853.
19. Weissleder, R.; Tung, C.-H.; Mahmood, U.; Bogdanov, A. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat. Biotech.,1999, 17(4), 375-378.
20. Chen, J.; Tung, C.-H.; Mahmood, U.; Ntziachristos, V.; Gyurko, R.; Fishman, M. C.; Huang, P. L.; Weissleder, R. In vivo imaging of proteolytic activity in atherosclerosis. Circulation, 2002, 105(23), 2766-2771.
21. Wunder, A.; Tung, C.-H.; Mller-Ladner, U.; Weissleder, R.; Mahmood, U. In vivo imaging of protease activity in arthritis: A novel approach for monitoring treatment response. Arthritis Rheumatism, 2004, 50(8), 2459-2465.
22. Law, B.; Hsiao, J. K.; Bugge, T. H.; Weissleder, R.; Tung, C. H. Optical zymography for specific detection of urokinase plasminogen activator activity in biological samples. Anal. Biochem., 2005, 338(1), 151-158.
23. Law, B.; Curino, A.; Bugge, T. H.; Weissleder, R.; Tung, C. H. Design, synthesis, and characterization of urokinase plasminogen-activator-sensitive nearinfrared reporter. Chem. Biol., 2004, 11 (1), 99-106.
24. Bremer, C.; Tung, C.-H.; Weissleder, R. Molecular Imaging of MMP Expression and Therapeutic MMP Inhibition. Academic Radiol., 2002, 9 (2), S314-S315.
25. Shah, K.; Tung, C.-H.; Chang, C.-H.; Slootweg, E.; OÄôLoughlin, T.; Breakefield, X. O.; Weissleder, R. In vivo imaging of HIV protease activity in amplicon vector-transduced gliomas. Cancer Res., 2004, 64(1), 273-278.
26. Tung, C.-H.; Mahmood, U.; Bredow, S.; Weissleder, R., In vivo imaging of proteolytic enzyme activity using a novel molecular reporter. Cancer Res., 2000, 60(17), 4953-4958.
27. [Lee, S.; Cha, E.-J.; Park, K.; Lee, S.-Y.; Hong, J.-K.; Sun, I.-C.; Kim, S. Y.; Choi, K.; Kwon, I. C.; Kim, K.; Ahn, C.-H. A nearinfrared-fluorescence-quenched gold-nanoparticle imaging probe for in vivo drug screening and protease activity determination13. Angewandte Chemie Intl Ed. Engl., 2008, 47(15), 2804-2807.
28. Chang, E.; Miller, J. S.; Sun, J.; Yu, W. W.; Colvin, V. L.; Drezek, R.; West, J. L. Protease-activated quantum dot probes. Biochem. Biophys. Res. Commun., 2005, 334 (4), 1317-1321.
29. Jang, K.-J.; Lee, H.; Jin, H.-L.; Park, Y.; Nam, J.-M., Restriction-Enzyme-Coded Gold-Nanoparticle Probes for Multiplexed DNA Detection. Small, 2009, 5 (23), 2665-2668.
30. Kim, Y.-P.; Oh, Y.-H.; Oh, E.; Ko, S.; Han, M.-K.; Kim, H.-S. Energy transfer-based multiplexed assay of proteases by using gold nanoparticle and quantum dot conjugates on a surface. Analyt. Chem., 2008, 80 (12), 4634-4641.
31. Sheth, R. A.; Tam, J. M.; Maricevich, M. A.; Josephson, L.; Mahmood, U. Quantitative Endovascular Fluorescence-based Molecular Imaging through Blood of Arterial Wall Inflammation1. Radiology, 2009, 251 (3), 813-821.
32. Kircher, M. F.; Weissleder, R.; Josephson, L. A dual fluorochrome probe for imaging proteases. Bioconjug. Chem., 2004, 15 (2), 242-248.
33. Melo, J. V. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood, 1996, 88(7), 2375-2384.
34. Druker, B. J.; Tamura, S.; Buchdunger, E.; Ohno, S.; Segal, G. M.; Fanning, S.; Zimmermann, J.; Lydon, N. B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med., 1996, 2 (5), 561-566.
35. Pendergast, A. M. In: The Abl Family Kinases: Mechanisms of Regulation and Signaling. Advances in Cancer Research, Academic Press: 2002; Vol. 85, pp 51-100.
36. Sato, M.; Ozawa, T.; Inukai, K.; Asano, T.; Umezawa, Y. Fluorescent indicators for imaging protein phosphorylation in single living cells. Nat. Biotech., 2002, 20(3), 287-294.
37. Zhang, J.; Ma, Y.; Taylor, S. S.; Tsien, R. Y. Genetically encoded reporters of protein kinase A activity reveal impact of substrate tethering. Proc.Natl. Acad. Sci.USA, 2001, 98(26), 14997-15002.
38. Nagai, Y.; Miyazaki, M.; Aoki, R.; Zama, T.; Inouye, S.; Hirose, K.; Iino, M.; Hagiwara, M. A fluorescent indicator for visualizing cAMP-induced phosphorylation in vivo. Nat. Biotech., 2000, 18 (3), 313-316.
39. Shults, M. D.; Imperiali, B. Versatile Fluorescence Probes of Protein Kinase Activity. J. Am. Chem. Soc., 2003, 125(47), 14248-14249.
40. Shults, M. D.; Janes, K. A.; Lauffenburger, D. A.; Imperiali, B. A multiplexed homogeneous fluorescence-based assay for protein kinase activity in cell lysates. Nat. Meth., 2005, 2 (4), 277-284.
41. Lee, C.-L.; Linton, J.; Soughayer, J. S.; Sims, C. E.; Allbritton, N. L. Localized measurement of kinase activation in oocytes of Xenopus laevis. Nat. Biotech., 1999, 17 (8), 759-762.
42. Zhang, H.-Z.; Kasibhatla, S.; Guastella, J.; Tseng, B.; Drewe, J.; Cai, S. X. N-Ac-DEVD-N' Äò-(Polyfluorobenzoyl)' àíR110:' Äâ Novel Cell-Permeable Fluorogenic Caspase Substrates for the Detection of Caspase Activity and Apoptosis. Bioconjug. Chem., 2003, 14 (2), 458-463.
43. McGrath, W. J.; Abola, A. P.; Toledo, D. L.; Brown, M. T.; Mangel, W. F. Characterization of human adenovirus proteinase activity in disrupted virus particles. Virology, 1996, 217 (1), 131-138.
44. Ho, N.-H.; Weissleder, R.; Tung, C.-H. Development of watersoluble far-red fluorogenic dyes for enzyme sensing. Tetrahedron, 2006, 62(4), 578-585.
45. Jiang, T.; Olson, E. S.; Nguyen, Q. T.; Roy, M.; Jennings, P. A.; Tsien, R. Y. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc. Natl. Acad. Sci. USA, 2004, 101(51), 17867-17872.
46. Olson, E. S.; Jiang, T.; Aguilera, T. A.; Nguyen, Q. T.; Ellies, L. G.; Scadeng, M.; Tsien, R. Y. Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. Proc. Natl. Acad. Sci. USA, 2010, 107(9), 4311-4316.
47. Olson, E. S.; Aguilera, T. A.; Jiang, T.; Ellies, L. G.; Nguyen, Q. T.; Wong, E. H.; Gross, L. A.; Tsien, R. Y. In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer. Integr. Biol. (Camb), 2009, 1 (5-6), 382-393.
48. Scherer, R. L.; VanSaun, M. N.; McIntyre, J. O.; Matrisian, L. M. Optical imaging of matrix metalloproteinase-7 activity in vivo using a proteolytic nanobeacon. Mol. Imaging, 2008, 7(3), 118-131.
49. Nguyen, Q. T.; Olson, E. S.; Aguilera, T. A.; Jiang, T.; Scadeng, M.; Ellies, L. G.; Tsien, R. Y. Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival. Proc. Natl. Acad. Sci. USA, 2010, 107(9), 4317-4322.
50. Zhang, Y.; So, M. K.; Rao, J. Protease-modulated cellular uptake of quantum dots. Nano. Lett., 2006, 6(9), 1988-1992.
51. Harris, T. J.; Maltzahn, G. Protease-triggered unveiling of bioactive nanoparticles. Small, 2008, 4 (9), 1307-1312.
52. de Wet, J. R.; Wood, K. V.; DeLuca, M.; Helinski, D. R.; Subramani, S. Firefly luciferase gene: structure and expression in mammalian cells. Mol. Cell. Biol., 1987, 7(2), 725-737.
53. Pfeifer, C. G.; Finlay, B. B. Monitoring gene expression of Salmonella inside mammalian cells: comparison of luciferase and [beta]- galactosidase fusion systems. J. Microbiol., Methods, 1995, 24 (2), 155-164.
54. Contag, C. H.; Bachmann, M. H. Advances in in vivo bioluminescence imaging of gene expression. Annu. Rev. Biomed. Eng., 2003, 4 (1), 235-260.
55. Wilson, T.; Hastings, J. W. Bioluminescence. Annual review of cell and developmental biology 2003, 14(1), 197-230.
56. Miska, W.; Geiger, R. A new type of ultrasensitive bioluminogenic enzyme substrates. I. Enzyme substrates with D-luciferin as leaving group. Biol. Chem. Hoppe Seyler, 1988, 369 (5), 407-11.
57. Monsees, T.; Miska, W.; Geiger, R. Synthesis and Characterization of a Bioluminogenic Substrate for [alpha]-Chymotrypsin. Analyt. Biochem., 1994, 221 (2), 329-334.
58. Cali, J. J.; Ma, D.; Sobol, M.; Simpson, D. J.; Frackman, S.; Good, T. D.; Daily, W. J.; Liu, D. Luminogenic cytochrome P450 assays. Exp. Opin. Drug Metab. Toxicol., 2006, 2 (4), 629-645.
59. Porter, A. G.; Janicke, R. U. Emerging roles of caspase-3 in apoptosis. Cell Death Differ., 1999, 6 (2), 99-104.
60. Laxman, B.; Hall, D. E.; Bhojani, M. S.; Hamstra, D. A.; Chenevert, T. L.; Ross, B. D.; Rehemtulla, A. Noninvasive realtime imaging of apoptosis. Proc. Natl. Acad. Sci. USA, 2002, 99(26), 16551-16555.
61. Shah, K.; Tung, C.-H.; Breakefield, X. O.; Weissleder, R. In vivo imaging of S-TRAIL-mediated tumor regression and apoptosis. Mol. Ther., 2005, 11(6), 926-931.
62. Otto-Duessel, M.; Khankaldyyan, V.; Gonzalez-Gomez, I.; Jensen, M. C.; Laug, W. E.; Rosol, M. In vivo testing of Renilla luciferase substrate analogs in an orthotopic murine model of human glioblastoma. Mol. Imaging, 2006, 5(2), 57-64.
63. Geiger, R.; Schneider, E.; Wallenfels, K.; Miska, W. A new ultrasensitive bioluminogenic enzyme substrate for betagalactosidase. Biol. Chem. Hoppe Seyler, 1992, 373(12), 1187-91.
64. Wehrman, T. S.; von Degenfeld, G.; Krutzik, P. O.; Nolan, G. P.; Blau, H. M. Luminescent imaging of [beta]-galactosidase activity in living subjects using sequential reporter-enzyme luminescence. Nat. Meth., 2006, 3(4), 295-301.
65. Degenfeld, G.; Wehrman, T. S.; Blau, H. M. Imaging β-galactosidase activity in vivo using sequential reporter-enzyme luminescence. Methods Mol. Biol., 2009, 574, 249-259.
66. Carriba, P.; Navarro, G.; Ciruela, F.; Ferre, S.; Casado, V.; Agnati, L.; Cortes, A.; Mallol, J.; Fuxe, K.; Canela, E. I.; Lluis, C.; Franco, R. Detection of heteromerization of more than two proteins by sequential BRET-FRET. Nat. Meth., 2008, 5(8), 727-733.
67. So, M.-K.; Xu, C.; Loening, A. M.; Gambhir, S. S.; Rao, J. Selfilluminating quantum dot conjugates for in vivo imaging. Nat. Biotech., 2006, 24 (3), 339-343.
68. Yao, H.; Zhang, Y.; Xiao, F.; Xia, Z.; Rao, J. Quantum dot/bioluminescence resonance energy transfer based highly sensitive detection of proteases13. Angewandte Chemie Intl. Ed, 2007, 46 (23), 4346-4349.
69. Kim, Y. P.; Daniel, W. L.; Xia, Z.; Xie, H.; Mirkin, C. A.; Rao, J. Bioluminescent nanosensors for protease detection based upon gold nanoparticle-luciferase conjugates. Chem. Commun., (Camb) 2010, 46 (1), 76-78.
70. Peterson, L. R.; Gropler, R. J. Radionuclide imaging of myocardial metabolism. Circ. Cardiovasc. Imag., 2010, 3(2), 211-222.
71. Lumachi, F.; Ferretti, G.; Povolato, M.; Bui, F.; Cecchin, D.; Marzola, M. C.; Zucchetta, P.; Basso, U. Axillary lymph node metastases detection with 99mtc-sestamibi scintimammography in patients with breast cancer undergoing curative surgery. Anticancer Res., 2007, 27 (4C), 2949-2952.
72. Kubota, K. From tumor biology to clinical PET: A review of positron emission tomography (PET) in oncology. Annal. Nuclear Med., 2001, 15(6), 471-486.
73. Rudd, J. H. F.; Myers, K. S.; Bansilal, S.; Machac, J.; Pinto, C. A.; Tong, C.; Rafique, A.; Hargeaves, R.; Farkouh, M.; Fuster, V.; Fayad, Z. A. Atherosclerosis inflammation imaging with 18F-FDG PET: Carotid, Iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J. Nuclear Med., 2008, 49(6), 871-878.
74. [Warburg, O. H.; Dickens, F.; Berlin. Kaiser Wilhelm-institut für biologie. [from old catalog], The metabolism of tumours. R. R. Smith: New York, 1931
75. Hustinx, R.; BÈnard, F.; Alavi, A. Whole-body FDG-PET imaging in the management of patients with cancer. Semin. Nuclear Med., 2002, 32(1), 35-46.
76. Alavi, A.; Reivich, M. Guest editorial: The conception of FDGPET imaging. Semin. Nuclear Med., 2002, 32(1), 2-5.
77. Larson, S. M.; Schwartz, L. H. 18F-FDG PET as a candidate for "qualified biomarker": functional assessment of treatment response in oncology. J. Nuclear Med., 2006, 47(6), 901-903.
78. Saito, Y.; Price, R.; Rottenberg, D.; Fox, J.; Su, T.; Watanabe, K.; Philips, F. Quantitative autoradiographic mapping of herpes simplex virus encephalitis with a radiolabeled antiviral drug. Science, 1982, 217(4565), 1151-1153.
79. Moolten, F. L. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res., 1986, 46(10), 5276-5281.
80. Balzarini, J.; de Clercq, E.; Ayusawa, D.; Seno, T. Murine mammary FM3A carcinoma cells transformed with the herpes simplex virus type 1 thymidine kinase gene are highly sensitive to the growth-inhibitory properties of (E)-5-(2-bromovinyl)-2'- deoxyuridine and related compounds. FEBS Lett., 1985, 185 (1), 95-100.
81. Tjuvajev, J. G.; Finn, R.; Watanabe, K.; Joshi, R.; Oku, T.; Kennedy, J.; Beattie, B.; Koutcher, J.; Larson, S.; Blasberg, R. G. Noninvasive imaging of herpes virus thymidine kinase gene transfer and expression: a potential method for monitoring clinical gene therapy. Cancer Res., 1996, 56(18), 4087-4095.
82. Jacobs, A.; Tjuvajev, J. G.; Dubrovin, M.; Akhurst, T.; Balatoni, J.; Beattie, B.; Joshi, R.; Finn, R.; Larson, S. M.; Herrlinger, U.; Pechan, P. A.; Chiocca, E. A.; Breakefield, X. O.; Blasberg, R. G. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo. Cancer Res., 2001, 61(7), 2983-2995.
83. Wang, H.-E.; Yu, H.-M.; Liu, R.-S.; Lin, M.; Gelovani, J. G.; Hwang, J.-J.; Wei, H.-J.; Deng, W.-P. Molecular imaging with 123I-FIAU, 18F-FUdR, 18F-FET, and 18F-FDG for monitoring herpes simplex virus type 1 thymidine kinase and ganciclovir prodrug activation gene therapy of cancer. J. Nuclear Med., 2006, 47(7), 1161-1171.
84. Vesselle, H.; Grierson, J.; Muzi, M.; Pugsley, J. M.; Schmidt, R. A.; Rabinowitz, P.; Peterson, L. M.; Valli√®res, E.; Wood, D. E. In Vivo Validation of 3'Ä≤deoxy-3'Ä≤-[18F]fluorothymidine ([18F]FLT) as a proliferation imaging tracer in humans. Clin. Cancer Res., 2002, 8(11), 3315-3323.
85. Sherley, J. L.; Kelly, T. J. Regulation of human thymidine kinase during the cell cycle. J. Biol. Chem., 1988, 263(17), 8350-8358.
86. Sugae, S.; Suzuki, A.; Takahashi, N.; Minamimoto, R.; Cheng, C.; Theeraladanon, C.; Endo, I.; Togo, S.; Inoue, T.; Shimada, H. Fluorine-18-labeled 5-fluorouracil is a useful radiotracer for differentiation of malignant tumors from inflammatory lesions. Annal. Nuclear Med., 2008, 22(1), 65-72.
87. Gunnar, B.; Matthias, E. B.; Uwe, H.; Ludwig, G.; Walter, J. L. Assessment of the biodistribution and metabolism of 5-fluorouracil as monitored by 18F PET and 19F MRI: A comparative animal study. Nuclear Med. Biol., 1996, 23 (7), 897-906.
88. Wang, K.; Kirichian, A. M.; Al Aowad, A. F.; Adelstein, S. J.; Kassis, A. I. Evaluation of chemical, physical, and biologic properties of tumor-targeting radioiodinated quinazolinone derivative. Bioconjug. Chem., 2007, 18(3), 754-764.
89. Ho, N.-h.; Harapanhalli, R. S.; Dahman, B. A.; Chen, K.; Wang, K.; Adelstein, S. J.; Kassis, A. I. Synthesis and biologic evaluation of a radioiodinated quinazolinone derivative for enzyme-mediated insolubilization therapy. Bioconjug. Chem., 2002, 13 (2), 357-364.
90. Beyer, T.; Townsend, D. W.; Brun, T.; Kinahan, P. E.; Charron, M.; Roddy, R.; Jerin, J.; Young, J.; Byars, L.; Nutt, R. A combined PET/CT scanner for clinical oncology. J. Nucl. Med., 2000, 41 (8), 1369-1379.
91. Nahrendorf, M.; Zhang, H.; Hembrador, S.; Panizzi, P.; Sosnovik, D. E.; Aikawa, E.; Libby, P.; Swirski, F. K.; Weissleder, R. Nanoparticle PET-CT Imaging of Macrophages in Inflammatory Atherosclerosis. Circulation, 2008, 117(3), 379-387.
92. Schipper, M. L.; Cheng, Z.; Lee, S.-W.; Bentolila, L. A.; Iyer, G.; Rao, J.; Chen, X.; Wu, A. M.; Weiss, S.; Gambhir, S. S. MicroPET-based biodistribution of quantum dots in living mice. J. Nucl. Med., 2007, 48(9), 1511-1518.
93. Xu, H.; Baidoo, K.; Gunn, A. J.; Boswell, C. A.; Milenic, D. E.; Choyke, P. L.; Brechbiel, M. W. Design, synthesis, and characterization of a dual modality positron emission tomography and fluorescence imaging agent for monoclonal antibody tumor-targeted imaging. J. Med. Chem., 2007, 50 (19), 4759-4765.
94. [Lee, H.; Akers, W. J.; Cheney, P. P.; Edwards, W. B.; Liang, K.; Culver, J. P.; Achilefu, S. Complementary optical and nuclear imaging of caspase-3 activity using combined activatable and radio-labeled multimodality molecular probe. J. Biomed. Optics, 2009, 14(4), 040507.
95. Marsden, P. K.; Strul, D.; Keevil, S. F.; Williams, S. C. R.; Cash, D. Simultaneous PET and NMR. Br. J. Radiol., 2002, 75 (90009), S53-59.
96. Shao, Y. Simultaneous PET and MR imaging. Phys. Med. Biol., 1997, 42 (10), 1965.
97. Suerbaum, S.; Michetti, P. Helicobacter pylori Infection. N. Engl. J. Med., 2002, 347 (15), 1175-1186.
98. Hazell, S. L.; Borody, T. J.; Gal, A.; Lee, A. Campylobacter pyloridis gastritis I: Detection of urease as a marker of bacterial colonization and gastritis. Am. J. Gastroenterol., 1987, 82 (4), 292-6.
99. Marshall, B. J.; Surveyor, I. Carbon-14 urea breath test forthe diagnosis of Campylobacter pylori associated gastritis. J. Nucl. Med., 1988, 29(1), 11-16.
100. Rauws, E. A.; Royen, E. A.; Langenberg, W.; Woensel, J. V.; Vrij, A. A.; Tytgat, G. N. 14Curea breath test in C pylori gastritis. Gut, 1989, 30(6), 798-803.
101. Kellar, K.E.P.; Fossheim, S.L.M.P.; Koenig, S.H.P. Magnetic field dependence of solvent proton relaxation by solute dysprosium(III) complexes. Invest. Radiol., 1998, 33(11),835-840
102. [Moats, R. A.; Fraser, S. E.; Meade, T. J. A "Smart" magnetic resonance imaging agent that reports on specific enzymatic activity. Angewandte Chemie Intl. Ed. Eng., 1997, 36 (7), 726-728.
103. Louie, A. Y.; Huber, M. M.; Ahrens, E. T.; Rothbacher, U.; Moats, R.; Jacobs, R. E.; Fraser, S. E.; Meade, T. J, In vivo visualization of gene expression using magnetic resonance imaging. Nat. Biotech., 2000, 18(3), 321-325.
104. Artemov, D.; Mori, N.; Ravi, R.; Bhujwalla, Z. M. Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res., 2003, 63 (11), 2723-2727.
105. Anelli, P. L.; Bertini, I.; Fragai, M.; Lattuada, L.; Luchinat, C.; Parigi, G. Sulfonamide-Functionalized Gadolinium DTPA Complexes as Possible Contrast Agents for MRI: A Relaxometric Investigation. Euro. J. Inorg., Chem., 2000, 2000(4), 625-630.
106. Hanaoka, K.; Kikuchi, K.; Terai, T.; Komatsu, T.; Nagano, T. A Gd3+-based magnetic resonance imaging contrast agent sensitive to beta-galactosidase activity utilizing a receptor-induced magnetization enhancement (RIME) phenomenon. Chem. A Euro. J., 2008, 14 (3), 987-995.
107. Nahrendorf, M.; Sosnovik, D.; Chen, J. W.; Panizzi, P.; Figueiredo, J.-L.; Aikawa, E.; Libby, P.; Swirski, F. K.; Weissleder, R. Activatable magnetic resonance imaging agent reports myeloperoxidase activity in healing infarcts and noninvasively detects the antiinflammatory effects of atorvastatin on ischemia-reperfusion injury. Circulation, 2008, 117(9), 1153-1160.
108. Querol, M.; Chen, J. W.; Weissleder, R.; Bogdanov, A. DTPA-bisamide-based MR sensor agents for peroxidase imaging. Organic Lett., 2005, 7 (9), 1719-1722.
109. Bogdanov Jr, A.; Matuszewski, L.; Bremer, C.; Petrovsky, A.; Weissleder, R. Oligomerization of paramagnetic substrates result in signal amplification and can be used for mr imaging of molecular targets. Mol. Imaging, 2002, 1 (1), 16-23.
110. Nivorozhkin, A. L.; Kolodziej, A. F.; Caravan, P.; Greenfield, M. T.; Lauffer, R. B.; McMurry, T. J. Enzyme-activated Gd3+ magnetic resonance imaging contrast agents with a prominentz receptor-induced magnetization enhancement. Angew. Chemie Intl. Edi., 2001, 40(15), 2903-2906.
111. Chen, J. W.; Breckwoldt, M. O.; Aikawa, E.; Chiang, G.; Weissleder, R. Myeloperoxidase-targeted imaging of active inflammatory lesions in murine experimental autoimmune encephalomyelitis. Brain, 2008, 131(4), 1123-1133.
112. Breckwoldt, M. O.; Chen, J. W.; Stangenberg, L.; Aikawa, E.; Rodriguez, E.; Qiu, S.; Moskowitz, M. A.; Weissleder, R. Tracking the inflammatory response in stroke in vivo by sensing the enzyme myeloperoxidase. Proc. Natl. Acad. Sci. USA, 2008, 105 (47), 18584-18589.
113. Rodriguez, E.; Nilges, M.; Weissleder, R.; Chen, J. W. Activatable Magnetic Resonance Imaging Agents for Myeloperoxidase Sensing: Mechanism of Activation, Stability, and Toxicity. J. Am. Chem. Soc., 2009, 132 (1), 168-177.
114. Aime, S.; Cabella, C.; Colombatto, S.; Crich, S. G.; Gianolio, E.; Maggioni, F. Insights into the use of paramagnetic Gd(III) complexes in MR-molecular imaging investigations. J. Magn.Resonance Imaging, 2002, 16(4), 394-406.
115. Himmelreich, U.; Aime, S.; Hieronymus, T.; Justicia, C.; Uggeri, F.; Zenke, M.; Hoehn, M. A responsive MRI contrast agent to monitor functional cell status. NeuroImage, 2006, 32 (3), 1142-1149.
116. Lebel, R.; Jastrz, B.; eogon; bska; Therriault, H.; Cournoyer, M.-M.; McIntyre, J. O.; Escher, E.; Neugebauer, W.; Paquette, B.; Lepage, M. Novel solubility-switchable MRI agent allows the noninvasive detection of matrix metalloproteinase-2 activity in vivo in a mouse model. Magn. Resonance Med., 2008, 60 (5), 1056-1065.
117. Jastrzebska, B.; Lebel, R.; Therriault, H.; McIntyre, J. O.; Escher, E.; Guérin, B.; Paquette, B.; Neugebauer, W. A.; Lepage, M. New enzyme-activated solubility-switchable contrast agent for magnetic resonance imaging: from synthesis to in vivo imaging. J. Med.l Chem., 2009, 52 (6), 1576-1581.
118. Ward, K. M.; Balaban, R. S. Determination of pH using water protons and chemical exchange dependent saturation transfer (CEST). Magnetic Resonance Med., 2000, 44 (5), 799-802.
119. Terreno, E.; Castelli, D. D.; Cravotto, G.; Milone, L.; Aime, S. Ln(III)-DOTAMGly complexes: A versatile series to assess the determinants of the efficacy of paramagnetic chemical exchange saturation transfer agents for magnetic resonance imaging applications. Invest. Radiol., 2004, 39(4), 235-243.
120. Li, A. X.; Wojciechowski, F.; Suchy, M.; Jones, C. K.; Hudson, R. H.; Menon, R. S.; Bartha, R. A sensitive PARACEST contrast agent for temperature MRI: Eu3+-DOTAM-glycine (Gly)- phenylalanine (Phe). Magn. Reson. Med., 2008, 59 (2), 374-381.
121. Aime, S.; Anelli, L.; Botta, M.; Brocchetta, M.; Canton, S.; Fedeli, F.; Gianolio, E.; Terreno, E. Relaxometric evaluation of novel manganese(II) complexes for application as contrast agents in magnetic resonance imaging. J. Biol. Inorg. Chem., 2002, 7 (1-2), 58-67.
122. Zhang, S.; Trokowski, R.; Sherry, A. D. A paramagnetic CEST agent for imaging glucose by MRI. J. Am. Chem. Soc., 2003, 125 (50), 15288-1529.
123. Yoo, B.; Pagel, M. D. A PARACEST MRI contrast agent to detect enzyme activity. J. Am. Chem. Soc., 2006, 128(43), 14032-14033.
124. Duimstra, J. A.; Femia, F. J.; Meade, T. J. A Gadolinium chelate for detection of OE??-glucuronidase:'Äâ A self-immolative approach. J. Am. Chem. Soc., 2005, 127(37), 12847-12855.
125. [Chauvin, T.; Durand, P.; Bernier, M.; Meudal, H.; Doan, B.-T.; Noury, F.; Badet, B.; Beloeil, J.-C.; TÛth, v. Detection of Enzymatic Activity by PARACEST MRI: A General Approach to Target a Large Variety of Enzymes13. Angew. Chemie Intl. Ed., 2008, 47(23), 4370-4372.
126. Rogers, W. J.; Meyer, C. H.; Kramer, C. M. Technology insight: in vivo cell tracking by use of MRI. Nat. Clin. Pract. Cardiovasc. Med., 2006, 3(10), 554-562.
127. Moore, A.; Grimm, J.; Han, B.; Santamaria, P. Tracking the recruitment of diabetogenic CD8+ T-cells to the pancreas in real time. Diabetes, 2004, 53 (6), 1459-1466.
128. Islam, T.; Josephson, L. Current state and future applications of active targeting in malignancies using superparamagnetic iron oxide nanoparticles. Cancer Biomarkers, 2009, 5 (2), 99-107.
129. Thorek, D. L.; Chen, A. K.; Czupryna, J.; Tsourkas, A. Superparamagnetic iron oxide nanoparticle probes for molecular imaging. Ann. Biomed. Eng., 2006, 34 (1), 23-38.
130. Perez, J. M.; Josephson, L.; O'Loughlin, T.; Hogemann, D.; Weissleder, R. Magnetic relaxation switches capable of sensing molecular interactions. Nat. Biotech., 2002, 20 (8), 816-820.
131. Perez, J. M.; O'Loughin, T.; Simeone, F. J.; Weissleder, R.; Josephson, L. DNA-based magnetic nanoparticle assembly acts as a magnetic relaxation nanoswitch allowing screening of DNAcleaving agents. J. Am. Chem. Soc., 2002, 124 (12), 2856-2857.
132. [Zhao, M.; Josephson, L.; Tang, Y.; Weissleder, R. Magnetic sensors for protease assays. Angew. Chemie Intl. Ed., 2003, 42(12), 1375-1378.
133. Perez, J. M.; Simeone, F. J.; Tsourkas, A.; Josephson, L.; Weissleder, R. Peroxidase substrate nanosensors for MR imaging. Nano Lett., 2003, 4 (1), 119-122.
134. Grimm, J.; Perez, J. M.; Josephson, L.; Weissleder, R. Novel nanosensors for rapid analysis of telomerase activity. Cancer Res., 2004, 64(2), 639-643.
135. Perez, J. M.; Grimm, J.; Josephson, L.; Weissleder, R. Integrated nanosensors to determine levels and functional activity of human telomerase. Neoplasia 2008, 10 (10), 1066-1072.
136. [Harris, T. J.; von Maltzahn, G.; Derfus, A. M.; Ruoslahti, E.; Bhatia, S. N. Proteolytic actuation of nanoparticle self-assembly. Angew. Chem. Int. Ed. Engl., 2006, 45 (19), 3161-3165.
137. Schellenberger, E.; Rudloff, F.; Warmuth, C.; Taupitz, M.; Hamm, B.; Schnorr, J. Protease-specific nanosensors for magnetic resonance imaging. Bioconjug. Chem., 2008, 19(12), 2440-2445.
138. [Westmeyer, G. G.; Durocher, Y.; Jasanoff, A. A secreted enzyme reporter system for MRI13. Angew. Chemie Intl. Ed., 2010, 49 (23), 3909-3911.
139. Taktak, S.; Sosnovik, D.; Cima, M. J.; Weissleder, R.; Josephson, L. Multiparameter magnetic relaxation switch assays. Analyt. Chem., 2007, 79(23), 8863-8869.
140. Lowery, T. J.; Palazzolo, R.; Wong, S. M.; Prado, P. J.; Taktak, S. Single-coil, multisample, proton relaxation method for magnetic relaxation switch assays. Analyt. Chem., 2008, 80 (4), 1118-1123.
141. [Koh, I.; Hong, R.; Weissleder, R.; Josephson, L. Sensitive NMR sensors detect antibodies to influenza. Angew. Chemie Intl. Ed., 2008, 47 (22), 4119-4121.
142. Lee, H.; Sun, E.; Ham, D.; Weissleder, R. Chip-NMR biosensor for detection and molecular analysis of cells. Nat. Med., 2008, 14(8), 869-874.
143. Koretsky, A. P.; Brosnan, M. J.; Chen, L. H.; Chen, J. D.; Van Dyke, T. NMR detection of creatine kinase expressed in liver of transgenic mice: determination of free ADP levels. Proc. Natl. Acad. Sci. USA, 1990, 87 (8), 3112-3116.
144. Srinivas, M.; Heerschap, A.; Ahrens, E. T.; Figdor, C. G.; Vries, I. J.M. 19F MRI for quantitative in vivo cell tracking. Trends Biotechnol., 2010, 28(7), 363-370.
145. Mizukami, S.; Takikawa, R.; Sugihara, F.; Hori, Y.; Tochio, H.; Walchli, M.; Shirakawa, M.; Kikuchi, K. Paramagnetic relaxationbased 19f MRI probe to detect protease activity. J. Am. Chem. Soc., 2008, 130(3), 794-795.
146. Mizukami, S.; Takikawa, R.; Sugihara, F.; Shirakawa, M.; Kikuchi, K., Dual-function probe to detect protease activity for fluorescence measurement and 19F MRI. Angew. Chem. Int. Ed. Engl., 2009, 48 (20), 3641.
147. Gade, T. P. F.; Koutcher, J. A.; Spees, W. M.; Beattie, B. J.; Ponomarev, V.; Doubrovin, M.; Buchanan, I. M.; Beresten, T.; Zakian, K. L.; Le, H. C.; Tong, W. P.; Mayer-Kuckuk, P.; Blasberg, R. G.; Gelovani, J. G. Imaging transgene activity in vivo. Cancer Res., 2008, 68 (8), 2878-2884.
148. Merritt, M. E.; Harrison, C.; Storey, C.; Jeffrey, F. M.; Sherry, A. D.; Malloy, C. R. Hyperpolarized 13C allows a direct measure of flux through a single enzyme-catalyzed step by NMR. Proc. Natl. Acad. Sci. USA, 2007, 104(50), 19773-19777.
149. Gabellieri, C.; Reynolds, S.; Lavie, A.; Payne, G. S.; Leach, M. O.; Eykyn, T. R. Therapeutic target metabolism observed using hyperpolarized 15N choline. J. Am. Chem. Soc., 2008, 130 (14), 4598-4599.
150. Albers, M. J.; Bok, R.; Chen, A. P.; Cunningham, C. H.; Zierhut, M. L.; Zhang, V. Y.; Kohler, S. J.; Tropp, J.; Hurd, R. E.; Yen, Y.- F.; Nelson, S. J.; Vigneron, D. B.; Kurhanewicz, J. Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. Cancer Res., 2008, 68 (20), 8607-8615.
151. Day, S. E.; Kettunen, M. I.; Gallagher, F. A.; Hu, D.-E.; Lerche, M.; Wolber, J.; Golman, K.; Ardenkjaer-Larsen, J. H.; Brindle, K. M. Detecting tumor response to treatment using hyperpolarized 13C magnetic resonance imaging and spectroscopy. Nat. Med., 2007, 13 (11), 1382-1387.
152. [Gaits, F.; Hahn, K. Shedding light on cell signaling: interpretation of FRET biosensors. Sci. STKE, 2003, 2003(165), pe 3
153. Cho, E. J.; Lee, J.-W.; Ellington, A. D. Applications of aptamers as sensors. Annu. Rev. Analyt. Chem., 2009, 2 (1), 241-264.
154. Jones, R.; Baker, M. B.; Weber, M.; Harrison, D. G.; Bao, G.; Searles, C. D. Molecular beacons can assess changes in expression and 3'-polyadenylation of human eNOS mRNA. Am. J. Physiol. Cell Physiol., 2009, 296(3), C498-504.
155. Hu, C.-D.; Kerppola, T. K., Simultaneous visualization of multiple protein interactions in living cells using multicolor fluorescence complementation analysis. Nat. Biotech., 2003, 21 (5), 539-545.
156. Bagalkot, V.; Zhang, L.; Levy-Nissenbaum, E.; Jon, S.; Kantoff, P. W.; Langer, R.; Farokhzad, O. C. Quantum dot aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett., 2007, 7 (10), 3065-3070.
157. [Blum, G.; Weimer, R. M.; Edgington, L. E.; Adams, W.; Bogyo, M. Comparative assessment of substrates and activity based probes as tools for non-invasive optical imaging of cysteine protease activity. PLoS One, 2009, 4(7), e6374.
158. Edgington, L. E.; Berger, A. B.; Blum, G.; Albrow, V. E.; Paulick, M. G.; Lineberry, N.; Bogyo, M. Noninvasive optical imaging of apoptosis by caspase-targeted activity-based probes. Nat. Med., 2009, 15(8), 967-973.
159. Potter, C.; Harris, A. L. Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle, 2004, 3 (2), 164-167.
160. [Carlin, S.; Khan, N.; Ku, T.; Longo, V. A.; Larson, S. M.; Smith-Jones, P. M. Molecular targeting of carbonic anhydrase IX in mice with hypoxic HT29 colorectal tumor xenografts. PLoS One, 2010, 5 (5), e10857.
161. Lawrentschuk, N.; Lee, F. T.; Jones, G.; Rigopoulos, A.; Mountain, A.; O'Keefe, G.; Papenfuss, A. T.; Bolton, D. M.; Davis, I. D.; Scott, A. M. Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and 124I-cG250 PET/CT. Urologic oncology: Semin. Original Investig., 2007, 29(4),411-420.
162. Divgi, C. R.; Pandit-Taskar, N.; Jungbluth, A. A.; Reuter, V. E.; Gnen, M.; Ruan, S.; Pierre, C.; Nagel, A.; Pryma, D. A.; Humm, J.; Larson, S. M.; Old, L. J.; Russo, P. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol., 2007, 8(4), 304-310.
163. Das, J.; Chen, P.; Norris, D.; Padmanabha, R.; Lin, J.; Moquin, R. V.; Shen, Z.; Cook, L. S.; Doweyko, A. M.; Pitt, S.; Pang, S.; Shen, D. R.; Fang, Q.; de Fex, H. F.; McIntyre, K. W.; Shuster, D. J.; Gillooly, K. M.; Behnia, K.; Schieven, G. L.; Wityak, J.; Barrish, J. C., 2-Aminothiazole as a novel kinase inhibitor template. Structure'àíactivity relationship studies toward the discovery of N- (2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5- carboxamide (Dasatinib, BMS-354825) as a potent pan-src kinase inhibitor. J. Med. Chem., 2006, 49 (23), 6819-6832.
164. [Bradbury, M.; Hambardzumyan, D.; Penate-Medina, O.; Pillarsetty, K.; Veach, D.; Holland, E.; Larson, S., 18F-Dasatinib as a novel biomarker for PDGFR-positive glioma transgenic mouse models. J. Nucl. Med. Meeting Abs., 2008, 49 (MeetingAbstracts1), 106P-a
165. Santos, E.; Veach, D.; Pillarsetty, N.; Punzalan, B.; Larson, S. Localization of human prostate cancer through PET imaging using a novel dasatinib analog in mice. J. Nucl. Med. Meeting Abs., 2008, 49 (MeetingAbstracts_1), 106P-b
166. Veach, D. R.; Namavari, M.; Pillarsetty, N.; Santos, E. B.; Beresten-Kochetkov, T.; Lambek, C.; Punzalan, B. J.; Antczak, C.; Smith-Jones, P. M.; Djaballah, H.; Clarkson, B.; Larson, S. M. Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib. J. Med. Chem., 2007, 50 (23), 5853-5857.
167. Funovics, M. A.; Weissleder, R.; Mahmood, U. Catheter-based in vivo imaging of enzyme activity and gene expression: feasibility study in mice1. Radiology, 2004, 231(3), 659-666.
168. Lu, M.; Cohen, M. H.; Rieves, D.; Pazdur, R. FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am. J. Hematol., 2010, 85(5), 315-319.
169. Ram, Z.; Culver, K. W.; Oshiro, E. M.; Viola, J. J.; DeVroom, H. L.; Otto, E.; Long, Z.; Chiang, Y.; McGarrity, G. J.; Muul, L. M.; Katz, D.; Michael Blaese, R.; Oldfield, E. H. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat. Med., 1997, 3(12), 1354-1361.
170. Trask, T. W.; Trask, R. P.; Aguilar-Cordova, E.; Shine, H. D.; Wyde, P. R.; Goodman, J. C.; Hamilton, W. J.; Rojas-Martinez, A.; Chen, S.-H.; Woo, S. L. C.; Grossman, R. G. Phase I Study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with recurrent malignant brain tumors. Mol. Ther., 2000, 1(2), 195-203.